In one paragraphArticle in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Xinyun XuDepartment of Nutrition, University of Tennessee, Knoxville, TN 37996, USA.
Christophe MorisseauDepartment of Entomology and Nematology, Comprehensive Cancer Center, University of California, Davis, CA 95616, USA.ORCID 0000-0002-5672-6631 Kin Sing Stephen LeeDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.ORCID 0000-0003-4541-3063 Bruce D HammockDepartment of Entomology and Nematology, Comprehensive Cancer Center, University of California, Davis, CA 95616, USA.ORCID 0000-0003-1408-8317 Jiangang ChenDepartment of Public Health, University of Tennessee, Knoxville, TN 37996, USA.
Funding
Supplement for bioactive lipids as effectors and indicators of the deleterious effects of human healthR35ES030443 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MORISSEAU, CHRISTOPHE HP · 2019 to 2025
$5.8MFerroptosis and Polyunsaturated Fatty Acid MetabolismR35GM146983 · NIGMS · MICHIGAN STATE UNIVERSITY · PI Kin Sing Stephen Lee · 2022 to 2026
$2.0Mn-3 PUFA derived epoxides and thermogenesis for obesity preventionR15DK132728 · NIDDK · UNIVERSITY OF TENNESSEE KNOXVILLE · PI ZHAO, LING · 2022 to 2022
$446kn-3 derived epoxides and sEH inhibitor in brown adipogenesisR15DK114790 · NIDDK · UNIVERSITY OF TENNESSEE KNOXVILLE · PI ZHAO, LING · 2018 to 2018
$443kNIDDK NIH HHS R15 DK114790NIDDK NIH HHS R15 DK132728NIEHS NIH HHS R35 ES030443NIEHS RIVER award R35 ES030443.NIGMS NIH HHS R35 GM146983NIH HHS 1R15DK132728
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Adipocytes, BrownAdipogenesisArachidonic AcidsEicosapentaenoic AcidEpoxide HydrolasesMitochondriaPhenylurea Compounds3T3-L1 CellsAdipose Tissue, BrownAnimalsBenzoatesCell RespirationMaleMiceMice, Inbred C57BLPPAR gamma17,18-epoxy-5,8,11,14-eicosatetraenoic acid4-(4-(3-(4-trifluoromethoxy-phenyl)ureido)cyclohexyloxy)benzoic acidArachidonic AcidsBenzoatesEicosapentaenoic AcidEpoxide HydrolasesPhenylurea CompoundsPPAR gamma17,18-EEQ19,20-EDPbrown adipogenesisn-3 epoxy fatty acidsoluble epoxide hydrolasesoluble epoxide hydrolase inhibitor t-TUCBthermogenesis
Identifiers
PMID40289939
PMCPMC11946110
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390